About StrideBio
StrideBio is a Healthcare company based in Durham (United States) founded in 2015. AAV-based gene therapies for rare diseases are developed. StrideBio has raised $98.2 million across 3 funding rounds from investors including ARE, Takeda Pharmaceuticals and Sarepta Therapeutics. The company has 109 employees. StrideBio offers products and services including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is STRIDEBIO, INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2015 and headquartered in Durham, United States, AAV-based gene therapies for rare diseases are developed within the biotechnology sector. Therapies are targeted at conditions including Friedreichs ataxia, Niemann-Pick disease type C, Angelman syndrome, Dravet syndrome, and Rett syndrome. Operations rely on a structure-inspired adeno-associated virus vector engineering platform to advance treatment options.
- Headquarters Durham, United States
- Employees 109
- SectorsHealthcare
- Email••••••••
- Website stridebio.com
- Social LinkedIn
- Legal Name Stridebio, Inc.
- Total Equity Funding$98.2M (USD)
in 3 rounds
- Latest Funding Round$81.5M (USD), Series B
Mar 2021
- InvestorsARE
& 11 more
- Employee Count109
Products & Services of StrideBio
StrideBio offers a comprehensive portfolio of products and services, including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline.
Platform for developing advanced gene therapies.
Service for producing AAV vectors used in gene therapy.
Pipeline of gene therapies targeting life-threatening diseases.
Funding Insights of StrideBio
StrideBio has successfully raised a total of $98.2M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $81.5 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $98.2M
- Total Rounds 3
- Last Round Series B — $81.5M
- First Round $1M
(Jun 2017)
- Investors Count 12
All 3 funding rounds of StrideBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $81.5M | Series B | – | Novo Holdings, Northpond Ventures | |
| Jun 2018 | $15.7M | Series A | – | Hatteras Venture Partners | |
| Jun 2017 | $1M | Seed | – | Hatteras Venture Partners | – |
12 investors in total: 12 institutional.
Investors in StrideBio
StrideBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Takeda Pharmaceuticals and Sarepta Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Investments in healthcare startups are managed by Octagon Capital Advisors. | octagoninvestments.com | New York, United States | ||
UCB Ventures is focused on strategic corporate venture investments. | 2017 | ucbventures.com | Brussels, Belgium | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
| takedaventures.com | ||||
Early stage investments focused VC firm | acks.com | |||
RNA-targeted therapeutics are developed for rare and infectious diseases. | 1980 | sarepta.com | Cambridge, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for StrideBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of StrideBio
12 people are tracked at StrideBio (2 in leadership, 7 in board & advisors, 3 in team); the tracked headcount is 109.
| Name | Role | Group |
|---|---|---|
Kevin Walton | VP of Corporate Development | Leadership |
Mike Reeves | VP, Human Resources | Leadership |
Erica Whitaker | Director | Board & advisors |
H. Stewart Parker > | Director | Board & advisors |
Mavis Agbandje-McKenna | Co-Founder & Director | Board & advisors |
Aravind Asokan | Co-Founder & Director | Board & advisors |
Karen Hong | Director | Board & advisors |
Shaan Gandhi | Director | Board & advisors |
Kristina Allikmets | Director | Board & advisors |
Jerry Taylor | Manager of Metrology and Facilities | Team |
Daniel Lawrence | Senior IT Infrastructure Engineer | Team |
Matthew Self | Lead Vector Production Specialist | Team |
Complete people profiles for StrideBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of StrideBio
3 dated milestones of StrideBio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded StrideBio is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $81.5M.
Competitors of StrideBio
StrideBio has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of StrideBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as StrideBio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stridebio
Complete news archive for StrideBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about StrideBio
StrideBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
StrideBio is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
StrideBio is a funded company, having raised a total of $98.2M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 2017.
StrideBio has 109 employees.
Founded in 2015 and headquartered in Durham, United States, AAV-based gene therapies for rare diseases are developed within the biotechnology sector. Therapies are targeted at conditions including Friedreichs ataxia, Niemann-Pick disease type C, Angelman syndrome, Dravet syndrome, and Rett syndrome. Operations rely on a structure-inspired adeno-associated virus vector engineering platform to advance treatment options.
StrideBio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
StrideBio offers STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline.
StrideBio has 12 investors. Key investors include ARE, Takeda Pharmaceuticals, Sarepta Therapeutics, Novo Holdings, and Pontifax Venture Capital.
StrideBio operates through Stridebio, Inc..